INNT - Today's Research Reports on Stocks to Watch: Innovate Biopharmaceuticals and TapImmune

NEW YORK, NY / ACCESSWIRE / September 4, 2018 / Both Innovate Biopharmaceuticals and TapImmune sprang to life on Friday seeing big gains after the companies announced plans to present at conferences this month.

RDI Initiates Coverage on:

Innovate Biopharmaceuticals, Inc.
https://rdinvesting.com/news/?ticker=INNT

TapImmune, Inc.
https://rdinvesting.com/news/?ticker=TPIV

Innovate Biopharmaceuticals, Inc. shares closed up 36.14% on about 4.1 million shares traded on Friday. The clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory diseases, announced that it plans to present at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 4-6, 2018 at the St. Regis Hotel in New York City. Innovate’s lead drug candidate, larazotide acetate, has a mechanism of action that renormalizes the dysfunctional intestinal barrier by decreasing intestinal permeability and reducing antigen trafficking, such as gliadin fragments in celiac disease, and bacterial toxins and immunogenic antigens in NASH. In several diseases, including celiac disease, NASH, Crohn’s disease, ulcerative colitis, and irritable bowel syndrome (IBS) the intestinal barrier is dysfunctional with increased permeability.

Access RDI’s Innovate Biopharmaceuticals, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=INNT

TapImmune, Inc. shares were up 19.23% on Friday with about 676,000 shares traded. There was no particular news from the company, which focuses on the development of novel immunotherapies for cancer, to explain the big jump. However it was announced last week that its President and CEO, Peter L. Hoang, will participate at two upcoming industry conferences. Mr. Hoang will present and participate in a panel discussion at the Hanson Wade CAR-TCR Summit on September 4-7, 2018, in Boston, Massachusetts, and present at BioCentury's 25th Annual NewsMakers in the Biotech Industry on September 7, 2018, in New York City. TapImmune's peptide or nucleic acid-based immunotherapeutic products comprise multiple naturally processed epitopes (NPEs) that are designed to comprehensively stimulate a patient's killer T cells and helper T cells, and to restore or further augment antigen presentation using proprietary nucleic acid-based expression systems. This unique approach can produce off-the-shelf T cell vaccine candidates that elicit a broad-based T cell response and can be used without respect to HLA type.

Access RDI’s TapImmune, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=TPIV

Our Actionable Research on Innovate Biopharmaceuticals, Inc. (NASDAQ: INNT) and TapImmune, Inc. (NASDAQ: TPIV) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com